Xilio Therapeutics (XLO) Capital Expenditures (2020 - 2026)

Xilio Therapeutics has disclosed Capital Expenditures across 7 years of filings, most recently posting $556000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $556000.0, up 90.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $782000.0 (up 154.72% YoY), and the FY2025 annual result was $518000.0, up 1338.89% from the prior year.
• Capital Expenditures came in at $556000.0 for Q1 2026 at Xilio Therapeutics, up from $95000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $771000.0 in Q2 2022 to a low of -$654000.0 in Q3 2022.
• The 5-year median for Capital Expenditures is $131000.0 (2025), against an average of $124230.8.
• Across the five-year window, Capital Expenditures plunged 673.68% in 2022 and soared 1483.33% in 2025, its largest moves.
• Xilio Therapeutics' Capital Expenditures stood at -$352000.0 in 2022, then surged by 189.77% to $316000.0 in 2023, then sank by 98.1% to $6000.0 in 2024, then jumped by 1483.33% to $95000.0 in 2025, then jumped by 485.26% to $556000.0 in 2026.
• The last three Capital Expenditures figures came in at $556000.0 (Q1 2026), $95000.0 (Q4 2025), and $131000.0 (Q2 2025), per Business Quant data.